Sort
10,766 grants matching “checkpoint inhibitor”
Inducing Lipid Peroxidation in Lymph Node Cancer Cells to Promote an Immunogenic Response
$49,538Cameron Scott Fraser · Harvard University D/B/A Harvard School Of Public Health · F31 · FY2025 · CA
Discovery and development of human origin recognition complex (ORC) inhibitors as a new class of anti-cancer agents
$49,538Jiancheng Mo · Johns Hopkins University · F31 · FY2025 · CA
TIGIT upholds peripheral tolerance in ICI-myocarditis
$49,538Camille Jaime · Johns Hopkins University · F31 · FY2025 · HL
Understanding the role of altered lipid metabolism in CD8 T cell exhaustion within the tumor microenvironment
$49,538Kellie Spahr · University Of Pittsburgh At Pittsburgh · F31 · FY2025 · CA
Pfn1âs Role in Genomic Stability and Immune Response in Breast Cancer
$49,538Ian Eder · University Of Pittsburgh At Pittsburgh · F31 · FY2025 · CA
Identifying metabolic targets to reinvigorate T cell exhaustion
$49,538Minsun Cha · Johns Hopkins University · F31 · FY2025 · AI
Improving Efficacy and Safety of VSV Immunotherapy for Metastatic Melanoma
$49,524Kevin G Shim · Mayo Clinic Rochester · F30 · FY2018 · CA
Immunoediting in Human Cancer
$49,524Ron S Gejman · Weill Medical Coll Of Cornell Univ · F30 · FY2018 · CA
Metabolic Contributions of Individual Cellular Compartments to the Diversity of the Tumor Microenvironment in Renal Cell Carcinoma
$49,513Bradley Reinfeld · Vanderbilt University · F30 · FY2022 · CA
Elucidating the mechanism of UL138 mediated suppression of lytic phase genes during human cytomegalovirus latency.
$49,511Christopher Gelbmann · University Of Wisconsin-Madison · F30 · FY2019 · AI
Developmental Therapeutics Research Program
$49,491John James Letterio · Case Western Reserve University · P30 · FY2019 · CA
GU Malignancies Research Program
$49,491Brian I Rini · Case Western Reserve University · P30 · FY2019 · CA
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
$49,194Brett Pogostin · Rice University · F99 · FY2023 · CA
Dissecting the tumor cell-immune TME axis to identify therapeutically actionable vulnerabilities that potentiate immunotherapy in GBM
$49,194Amanda Johnson · Johns Hopkins University · F99 · FY2023 · CA
Research Program
$49,109Anna Karolina Palucka · Jackson Laboratory · P30 · FY2020 · CA
Research Program
$49,109Jennifer Jean Trowbridge · Jackson Laboratory · P30 · FY2022 · CA
Research Program
$49,109Jennifer Jean Trowbridge · Jackson Laboratory · P30 · FY2021 · CA
Research Program
$49,107Jennifer Jean Trowbridge · Jackson Laboratory · P30 · FY2023 · CA
Therapeutic and Sustained Cytokine Delivery at the Tumor Site Using Engineered Mononuclear Cells
$49,044Patrick Sean Donahue · Northwestern University · F30 · FY2017 · CA
Immunoediting in Human Cancer
$49,044Ron S Gejman · Weill Medical Coll Of Cornell Univ · F30 · FY2017 · CA
Targeting TERT in Melanoma
$49,013Jessie Villanueva · Wistar Institute · R01 · FY2020 · CA
Post-translational Surveillance of Genome Expression
$48,997Richard Norman Sifers · Baylor College Of Medicine · R01 · FY2009 · DK
Validation of WEE1 kinase as a clinical target in KRAS-mutant pancreatic cancer
$48,989John Nathaniel Diehl · Univ Of North Carolina Chapel Hill · F30 · FY2022 · CA
Chk1 and Chk2 in Human Cancer Cells
$48,976Deborah F Wilsker · Johns Hopkins University · F32 · FY2008 · CA
TIGIT upholds peripheral tolerance in ICI-myocarditis
$48,974Camille Jaime · Johns Hopkins University · F31 · FY2024 · HL